Table 2. Factors associated with the development of new CMBs.
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Variables | Odds ratio | 95% CI | P value | Odds ratio | 95% CI | P value |
| Age, 1y increase | 1.050 | 0.982–1.124 | 0.152 | |||
| Male | 1.066 | 0.372–3.058 | 0.905 | |||
| Hypertension | 1.001 | 0.348–2.870 | 0.999 | |||
| Diabetes | 2.308 | 0.661–8.053 | 0.190 | |||
| eGFR < 60 ml/min/1.73 m2 | 1.900 | 0.350–5.473 | 0.234 | |||
| PVH or DWMH > Fazekas grade 1 | 3.400 | 1.107–10.45 | 0.033 | 2.088 | 0.579–7.529 | 0.261 |
| Multiple SLIs | 2.720 | 0.845–9.620 | 0.126 | |||
| CHADS2 score | 1.669 | 0.932–2.988 | 0.085 | 1.179 | 0.779–1.785 | 0.436 |
| CHA2DS2-VASc score | 1.310 | 0.917–1.872 | 0.138 | |||
| Baseline CMBs (+) | 3.782 | 1.216–11.76 | 0.022 | 4.156 | 1.196–14.44 | 0.025 |
| Antiplatelet drug use | 2.644 | 0.742–9.420 | 0.134 | |||
| Follow-up period, 1y increase | 1.361 | 0.814–2.277 | 0.235 | |||
| WF use vs DOAC use | 3.250 | 1.077–9.804 | 0.036 | 3.383 | 1.020–11.42 | 0.046 |
eGFR: estimated glomerular filtration rate, PVH: perivascular hyperintensity, DWMH: diffuse white matter hyperintensity.
SLIs: silent lacunar infarcts, CMBs: cerebral microbleeds, WF: warfarin, DOAC: direct oral anticoagulant.